RI

Repair Impact Fund

Europe, Hovedstaden, Denmark, Hellerup

Description

The aim of REPAIR Impact Fund is to increase humanity’s therapeutic arsenal in the fight against antimicrobial resistance.

Investor Profile

Repair Impact Fund has made 12 investments, with 0 in the past 12 months and 75% as lead.

Stage Focus

  • Series Unknown (33%)
  • Series A (25%)
  • Series B (17%)
  • Series C (8%)
  • Grant (8%)
  • Post Ipo Equity (8%)

Country Focus

  • United States (33%)
  • Denmark (25%)
  • Switzerland (25%)
  • United Kingdom (8%)
  • France (8%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Life Science
  • Wellness
  • Biopharma
  • Therapeutics
  • Service Industry
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Repair Impact Fund frequently co-invest with?

Wellington Partners
Europe, Bayern, Germany, Munich
Co-Investments: 2
LI
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 2
Tenmile
Oceania, Western Australia, Australia, Perth
Co-Investments: 2
AXA Investment Managers
Europe, Ile-de-France, France, Puteaux
Co-Investments: 2
Industrifonden
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 2
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 2
Pureos Bioventures
Europe, Zurich, Switzerland, Küsnacht
Co-Investments: 1
Adjuvant Capital
North America, New York, United States, New York
Co-Investments: 4
Sanofi Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Sunstone Life Science Ventures
Europe, Hovedstaden, Denmark, Copenhagen
Co-Investments: 3

What are some of recent deals done by Repair Impact Fund?

LimmaTech Biologics

Schlieren, Zurich, Switzerland

LimmaTech Biologics AG is a clinical stage biopharmaceutical company.

BiopharmaBiotechnology
Series AFeb 1, 2024
Amount Raised: $3,000,000
Revagenix

San Mateo, California, United States

Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs.

BiotechnologyPharmaceuticalService Industry
Series BJan 5, 2024
LimmaTech Biologics

Schlieren, Zurich, Switzerland

LimmaTech Biologics AG is a clinical stage biopharmaceutical company.

BiopharmaBiotechnology
Series AOct 9, 2023
Amount Raised: $36,462,275
Minervax

Hellerup, Hovedstaden, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

BiotechnologyHealth CareLife ScienceMedicalWellness
Series CDec 15, 2022
Amount Raised: $23,405,251
Minervax

Hellerup, Hovedstaden, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

BiotechnologyHealth CareLife ScienceMedicalWellness
Series BDec 15, 2020
Amount Raised: $57,612,508
Mutabilis

Paris, Ile-de-France, France

Mutabilis is discovery of new therapeutic targets for the development of anti-infectives.

Biotechnology
Series UnknownJan 6, 2020
Amount Raised: $7,836,148
IBT Vaccines

Rockville, Maryland, United States

IBT Vaccines is a biotechnology company.

Biotechnology
Series UnknownJan 6, 2020
Amount Raised: $3,900,000
Revagenix

San Mateo, California, United States

Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs.

BiotechnologyPharmaceuticalService Industry
Series AJan 1, 2020
Amount Raised: $4,000,000
Curza

Salt Lake City, Utah, United States

Curza is a small-molecule therapeutics company provides proprietary drugs focused on infectious diseases and oncology.

BiotechnologyHealth CareOncologyTherapeutics
Series UnknownJul 25, 2019
Amount Raised: $5,250,000
Procarta Biosystems

Norwich, Norfolk, United Kingdom

Procarta Biosystems develops antibacterials through an adaptable DNA-based platform to counter the rise of drug-resistant bacterial strains.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Series UnknownMar 5, 2019
Amount Raised: $1,695,916